Evogene Ltd. - Ordinary Shares (EVGN)
1.5600
+0.1000 (6.85%)
Evogene Ltd is a biotechnology company focused on enhancing the productivity and sustainability of the agriculture industry through the development of innovative biological solutions
The company leverages advanced computational biology and data-driven approaches to identify and engineer novel traits in plants, aiming to improve crop performance and resilience. By utilizing its proprietary technology platform, Evogene collaborates with industry partners to create products that address critical challenges such as pest resistance, drought tolerance, and nutrient efficiency in various agricultural sectors.
Previous Close | 1.460 |
---|---|
Open | 1.480 |
Bid | 1.450 |
Ask | 1.570 |
Day's Range | 1.480 - 1.562 |
52 Week Range | 1.200 - 10.40 |
Volume | 34,951 |
Market Cap | - |
PE Ratio (TTM) | - |
EPS (TTM) | - |
Dividend & Yield | N/A (N/A) |
1 Month Average Volume | 26,610 |
News & Press Releases
![](https://investorplace.com/wp-content/uploads/2022/05/earnings-season-1600.png)
EVGN stock results show that Evogene missed analyst estimates for earnings per share but beat on revenue for the second quarter of 2024.
Via InvestorPlace · August 22, 2024
![](https://investorplace.com/wp-content/uploads/2022/05/earnings-season-1600.png)
EVGN stock results show that Evogene beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024.
Via InvestorPlace · May 23, 2024
![](https://investorplace.com/wp-content/uploads/2022/05/earnings-season-1600.png)
EVGN stock results show that Evogene beat analyst estimates for earnings per share but missed on revenue for the fourth quarter of 2023.
Via InvestorPlace · March 7, 2024
![](https://cdn.benzinga.com/files/images/story/2023/analyst_ratings_image_0.png?width=1200&height=800&fit=crop)
Via Benzinga · August 18, 2023
![](https://cdn.benzinga.com/files/images/story/2024/pepi-stojanovski-MJSFNZ8BAXw-unsplash.jpeg?width=1200&height=800&fit=crop)
Evogene Ltd. released its fourth-quarter and full-year 2023 financial results, showing a 237% revenue increase for the year. Despite a 12% revenue decrease in Q4, the Israeli cannabis company reported $5.6 million in total revenue for the year. CEO Ofer Haviv highlighted the company's successful collaborations with industry leaders like Corteva, ICL, and Syngenta, contributing to revenue growth. In Q4, gross profit decreased to $180,000, but net financing income rose to $287,000. Total operating expenses increased to $7.8 million, leading to a net loss of $7.3 million. For the full year, gross profit reached $3.9 million, and net financing income was approximately $521,000. Evogene also secured partnerships with Verb Biotics and Colors Farm, along with receiving a €1.2 million EU grant for its Ag-Seed Division's research and development efforts.
Via Benzinga · March 7, 2024
![](https://cdn.benzinga.com/files/images/story/2023/rick-proctor-PGc9Vid8O24-unsplash.jpeg?width=1200&height=800&fit=crop)
Evogene reports a strong Q3 with $3.8M revenue and significant gross profit growth, showcasing resilience and innovation in cannabis tech.
Via Benzinga · November 16, 2023
![](https://cdn.benzinga.com/files/images/story/2023/analyst_ratings_image_3.png?width=1200&height=800&fit=crop)
Via Benzinga · October 2, 2023
![](https://cdn.benzinga.com/files/images/story/2023/07/03/evgn.png?width=1200&height=800&fit=crop)
Evogene Ltd. (NASDAQEVGN) said its unit Casterra Ag Ltd.
Via Benzinga · July 3, 2023
![](https://talkmarkets.com/images/logos/talkmarkets.png)
TalkMarkets.com announces a company spotlight series featuring Evogene (NASDAQEVGN), an agri-tech and bio-tech company with a computational predictive biological platform technology.
Via Talk Markets · June 22, 2023
![](https://cdn.benzinga.com/files/images/story/2023/earnings_image.jpeg?width=1200&height=800&fit=crop)
Companies Reporting Before The Bell • CI&T (NYSECINT) is estimated to report quarterly earnings at $0.06 per share on revenue of $106.08 million.
Via Benzinga · March 7, 2024
![](https://cdn.benzinga.com/files/images/story/2023/09/21/chart-1905225.jpg?width=1200&height=800&fit=crop)
Evogene Ltd (NASDAQEVGN) shares are trading lower by 5.9% to $0.63 Thursday morning after the company received a letter from the Nasdaq indicating that the company is not in compliance with the minimum bid price rule.
Via Benzinga · September 21, 2023
![](https://cdn.benzinga.com/files/images/story/2023/08/17/cannabis_debt_nikolayfrolochkin_and_ganjaspliffstoreuk_by_pixabay13.jpg?width=1200&height=800&fit=crop)
Cannabis company Evogene Ltd.
Via Benzinga · August 17, 2023
![](https://cdn.benzinga.com/files/images/story/2023/07/17/image21.jpeg?width=1200&height=800&fit=crop)
Gainers ProMIS Neurosciences, Inc. (NASDAQPMN) shares jumped 126.6% to $6.37. ProMIS showcased preclinical data at the Alzheimer's Association International Conference 2023 on computationally-derived antibody and vaccine from Alzheimer's pipeline.
Via Benzinga · July 17, 2023
![](https://cdn.benzinga.com/files/images/story/2023/07/17/cannabis_stocks_going_down_stefan_balaz_by_shutterstock_and_peter_pike_by_pixabay.jpg?width=1200&height=800&fit=crop)
Evogene Ltd. (NASDAQEVGN) (TASE:EVGN) shares were trading 20% lower at $1.12 per share at the time of writing Monday morning.
Via Benzinga · July 17, 2023
![](https://cdn.benzinga.com/files/images/story/2023/07/14/image9.jpg?width=1200&height=800&fit=crop)
Gainers Ainos, Inc. (NASDAQAIMD) shares surged 108.2% to $1.52 in pre-market trading after gaining around 7% on Thursday.
Via Benzinga · July 14, 2023
TalkMarkets Announces Company Spotlight Featuring Evogene
TalkMarkets.com announces a company spotlight series featuring Evogene (NASDAQEVGN), an agri-tech (agricultural technology) and bio-tech company with a computational predictive biological platform technology that it leverages to five relatively early-stage subsidiaries: three of which have reached the commercialization phase.
Via TheNewswire.com · June 22, 2023
![](https://public.newsdirect.com/392126460/90Mb8TWH.png)
TalkMarkets.com announces a company spotlight series featuring Evogene (NASDAQEVGN), an agri-tech and bio-tech company with a computational predictive biological platform technology.
Via News Direct · June 22, 2023
![](https://talkmarkets.com/images/logos/talkmarkets.png)
From a sum-of-parts perspective, Evogene is likely worth many multiples of its market valuation today, even without ascribing any value to Evogene’s technology.
Via Talk Markets · June 22, 2023
![](https://cdn.benzinga.com/files/images/story/2023/06/21/toughbuilt_industries_-_logo.jpg?width=1200&height=800&fit=crop)
Gainers Advanced Health Intelligence Ltd. (NASDAQAHI) shares jumped 209.5% to $2.29 after the company signed a Letter of Intention with UAE-Based e-script medicine management company Pharmak Pharmacy.
Via Benzinga · June 21, 2023